
Oncology NEWS International
- Oncology NEWS International Vol 4 No 4
- Volume 4
- Issue 4
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation
SAN DIEGO--Genta Jago, a joint venture between Genta Incorporated and Jagotec AG (Hergiswil, Switzerland), has filed an Investigational New Drug application with the FDA for a controlled-release formulation of zidovudine (AZT), marketed
SAN DIEGO--Genta Jago, a joint venture between Genta Incorporatedand Jagotec AG (Hergiswil, Switzerland), has filed an InvestigationalNew Drug application with the FDA for a controlled-release formulationof zidovudine (AZT), marketed by Burroughs Wellcome Co. as Retrovir.
The recommended dosage for AZT in the United States is six timesdaily. Results of pilot in vitro and human pharmacokinetic studiesin Europe suggest that once- or twice-daily dosing may be possiblewith the controlled-release formulation, which incorporates Jagotec'sGeomatrix delivery technology.
Articles in this issue
almost 31 years ago
First Results of Avicidin Trialsalmost 31 years ago
Chemo Patients Often Develop Menstrual Irregularitiesalmost 31 years ago
Growth Factor Receptor Blockade Moving From Laboratory to Clinicalmost 31 years ago
Vinorelbine Plus Chemo Promising in Advanced Diseasealmost 31 years ago
Bone Substudy a Part of Tamoxifen Prevention Trialalmost 31 years ago
Ultrasound Breast Screens Useful in Selected Womenalmost 31 years ago
New Roles Forecast for Endocrine Therapyalmost 31 years ago
Antisense Drug Against BCL-2 Effective in Animal Cancer Modelsalmost 31 years ago
Anticancer Drugs From Zeneca in Regulatory Phase of Developmentalmost 31 years ago
Osteosarcoma Chemo Regimens DebatedNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


































